SLC5A2 and type 2 diabetes mellitus: In twostudies in Japanese patients, tofogliflozin reduced cIMT to a similar degree with other antidiabetic agents [15], whereas SGLT2 inhibitors had no effect on cIMT in patients with T2DM and heart failure [16].